Asunaprevir Pharmacokinetics and Safety in Subjects With Impaired Renal Function

被引：0
|
作者：
Garimella, Tushar [1 ]
He, Bing [1 ]
Luo, Wen-Lin [2 ]
Colston, Elizabeth [1 ]
Zhu, Kurt [1 ]
Kandoussi, Hamza [2 ]
Marbury, Thomas C. [3 ]
Alcorn, Harry W. [4 ]
Smith, William B. [5 ]
Eley, Timothy [1 ]
机构：
[1] Bristol Myers Squibb Co, Res & Dev, Hopewell, NJ USA
[2] Bristol Myers Squibb Co, Res & Dev, Lawrenceville, NJ USA
[3] Orlando Clin Res Ctr, Orlando, FL USA
[4] DaVita Clin Res, Minneapolis, MN USA
[5] New Orleans Ctr Clin Res, Knoxville, TN USA
来源：
HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
463
引用
收藏
页码：430A / 430A
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
    Berg, Jolene K.
    Tzanis, Evan
    Garrity-Ryan, Lynne
    Bai, Stephen
    Chitra, Surya
    Manley, Amy
    Villano, Stephen
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (02)
  • [2] Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function
    Khosravan, Reza
    Toh, Melvin
    Garrett, May
    La Fargue, JoAnn
    Ni, Grace
    Marbury, Thomas C.
    Swan, Suzanne K.
    Lunde, Norman M.
    Bello, Carlo L.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04): : 472 - 481
  • [3] Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
    Borin, Marie T.
    Lo, Arthur
    Barnes, Chris N.
    Pendyala, Srikanth
    Bourdet, David L.
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 2305 - 2318
  • [4] Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
    Miyazawa, Y
    Blum, RA
    Schentag, JJ
    Kamimura, H
    Matsushima, H
    Swarz, H
    Ito, Y
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (09): : 603 - 621
  • [5] PHARMACOKINETICS AND SAFETY OF ELAFIBRANOR IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION
    Noel, Benoit
    Vargas, Dawn
    Georges-Coty, Anne
    Roudot, Alice
    Roux, Olivier
    Magrez, David
    Wyatt, David
    Birman, Pascal
    Addy, Carol
    [J]. HEPATOLOGY, 2021, 74 : 772A - 773A
  • [6] Pharmacokinetics, Safety, and Tolerability of Maraviroc in HIV-Negative Subjects with Impaired Renal Function
    Vourvahis, Manoli
    Fang, Juanzhi
    Checchio, Tina
    Milton, Ashley
    Weatherley, Barry
    McFadyen, Lynn
    Heera, Jayvant
    [J]. HIV CLINICAL TRIALS, 2013, 14 (03): : 99 - 109
  • [7] Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function
    Tao, Jun
    Liu, Shuaibing
    Zhao, Ying Ying
    Qi, Lei
    Yan, Pangke
    Wu, Nan
    Liu, Xiao
    Liu, Dongwei
    Tian, Xin
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [8] Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function
    Cawello, W
    Braun, M
    Horstmann, R
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1091 - 1091
  • [9] The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function
    Aweeka, F
    Jayesekara, D
    Horton, M
    Swan, S
    Lambrecht, L
    Wilner, KD
    Sherwood, J
    Anziano, RJ
    Smolarek, TA
    Turncliff, RZ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 : 27S - 33S
  • [10] Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function
    Gordi, Toufigh
    Blackburn, Brent
    Lieu, Hsiao
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (07): : 825 - 833
12345